Cargando…
PROTACs: Walking through hematological malignancies
Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that uses the proteasome ubiquitin system to target proteins of interest and promote their degradation with remarkable selectivity. Importantly, unlike conventional small molecule inhibitors, PROTACs have proven highly e...
Autores principales: | Bou Malhab, Lara J., Alsafar, Habiba, Ibrahim, Saleh, Rahmani, Mohamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994433/ https://www.ncbi.nlm.nih.gov/pubmed/36909156 http://dx.doi.org/10.3389/fphar.2023.1086946 |
Ejemplares similares
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020) -
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
por: Qi, Si-Min, et al.
Publicado: (2021) -
Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021) -
Application of cell-derived exosomes in the hematological malignancies therapy
por: Ghaffari, Kazem, et al.
Publicado: (2023) -
PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)